Hims & Hers Health Inc.(HIMS)今日盘前大跌近18%,引发市场广泛关注。主要因为美国FDA宣布诺和诺德的減肥药Wegovy供应短缺问題已获解决,这可能会限制Hims & Hers继续在其线上平台销售这种药物的复方版本。
在Wegovy短缺期间,FDA曾允许药房和远程医疗公司生产并销售该药的仿制版本。但现在短缺问题得到解决,FDA要求违规生产复方药品的公司在60-90天内停止。Hims & Hers警告称,虽然公司仍在寻求继续提供复方GLP-1药品的合法途径,但未来能否持续供应同样范围存在重大不确定性。
与此同时,Hims & Hers在第四季度财报中称,如果不能继续销售复方GLP-1药物,其2025年减肥药业务营收至少将下降约一半至7.25亿美元。这加重了市场对公司未来获利前景的担忧。尽管公司季度营收和盈利均超出预期,但毛利率低于预期,也引发了一定质疑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.